Form 4: Imunon General Counsel Granted Stock Options

Imunon, Inc.'s General Counsel and Corporate Secretary, Susan Eylward, was granted 8,251 stock options with an exercise price of $3.95.

Summary

• Susan Eylward, General Counsel and Corporate Secretary of Imunon, Inc. (IMNN), was granted 8,251 stock options.
• The transaction date for the grant was January 2, 2026.
• Each stock option has an exercise price of $3.95, which represents the closing price of Imunon, Inc. Common Stock on the grant date.
• The options will vest in a staggered manner: 50% on the grant date (January 2, 2026), 25% on the one-year anniversary of the grant date, and the remaining 25% on the second-year anniversary of the grant date.
• The expiration date for these stock options is January 2, 2036.
• Following this transaction, Susan Eylward beneficially owns 8,251 derivative securities directly.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (stock option grant), which is generally viewed as a neutral to slightly positive development as it aligns management incentives with shareholder interests, without indicating any significant operational or financial changes.

Positives

• The grant of stock options aligns the interests of the General Counsel and Corporate Secretary with those of shareholders, incentivizing long-term company performance.
• The exercise price of $3.95 per option matches the closing price of the common stock on the grant date, indicating a standard compensation practice.

Future Outlook

The vesting schedule of the stock options extends over two years, indicating a long-term incentive structure for the General Counsel and Corporate Secretary.

Industry Context

The grant of stock options to key executives is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and incentivize management by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• Granting stock options as part of executive compensation is a standard practice across various industries, including biotechnology, aligning executive interests with shareholder value.
• The vesting schedule, with a portion vesting immediately and the remainder over two years, is a typical approach to encourage executive retention and long-term commitment, comparable to practices at companies like Pfizer or Moderna for similar roles.

Stakeholder Impact

• Shareholders: The grant of stock options to a key executive can be seen as a positive for shareholders, as it aligns the executive's financial interests with the company's stock performance, potentially motivating decisions that enhance shareholder value.

Next Steps

• The stock options will continue to vest according to the schedule: 25% on January 2, 2027, and 25% on January 2, 2028.

Key Dates

Keywords

Imunon, IMNN, stock options, insider transaction, executive compensation, Form 4, corporate governance